Skip Navigation
Find a Doctor
 
 
 
 

 

Photo of Dr. Edward W Gabrielson, MD

Edward W Gabrielson, MD

Professor of Pathology
Male
Appointment Phone

410-502-5250

Main Location

The Johns Hopkins Hospital

View All Locations
Out-of-State & International Patients +
Out of State Patients

Call 410-464-6641 (8a.m. to 6p.m., EST, Mon-Fri)

Learn more about our out-of-state patient services »

International Patients

Call +1-410-502-0773 (7a.m. to 6p.m., EST, Mon-Fri)

Learn more about our international patient services »

Titles

  • Professor of Pathology
  • Professor of Oncology

Expertise

Breast Cancer, Esophageal Cancer, Lung Cancer, Pathology

Research Interests

Biomarkers; Lung cancer; Breast cancer; Esophageal cancer

Biography

Dr. Edward W. Gabrielson is a professor of pathology and oncology at the Johns Hopkins University School of Medicine. He specializes in molecular pathology, with particular emphasis on the pathology of breast, esophageal and lung cancers. Dr. Gabrielson serves as the co-director of the graduate program in pathobiology.

He received his M.D. from Northwestern University in 1977. He conducted a residency in pathology at the University of Colorado School of Medicine in 1982, and completed a fellowship in pathology at the National Institutes of Health in 1985.

Dr. Gabrielson has authored or co-authored numerous peer-reviewed publications, and is board certified in Anatomic and Clinical Pathology.

Languages

  • English

Additional Resources

Additional Resources +
  • Education +

    Training

    • Northwestern University The Feinberg School of Medicine (Chicago IL ) (1977)

    Residencies

    • University of Colorado School of Medicine / Pathology (Denver CO ) (1982)

    Fellowships

    • National Institutes of Health / Pathology (Bethesda MD ) (1985)

    Certifications

    • American Board of Pathology / Anatomic & Clinical Pathology (1983)
  • Research & Publications +

    Research Summary

    Dr. Gabrielson investigates the molecular biology of breast cancer and lung cancer, emphasizing aspects that have potential clinical significance. Current areas of emphasis include molecular classification of cancers, genetic instability in cancer, and functional changes in cancers related to cell-cell interactions and cellular metabolism.

    Selected Publications

    1. Gabrielson, E. Worldwide trends in lung cancer pathology. Respirology. 2006 Sep;11(5):533-538.
    2. Mao, T.L.; Hsu, C.Y.; Yen, M.J.; Gilks, B.; Sheu, J.J.; Gabrielson, E.; Vang, R.; Cope, L.; Kurman, R.J.; Wang, T.L.; Shih Ie, M. Expression of Rsf-1, a chromatin-remodeling gene, in ovarian and breast carcinoma. Hum Pathol. 2006 Sep;37(9):1169-1175.
    3. Singh, A.; Misra, V.; Thimmulappa, R.K.; Lee, H.; Ames, S.; Hoque, M.O.; Herman, J.G.; Baylin, S.B.; Sidransky, D.; Gabrielson, E.; Brock, M.V.; Biswal, S. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med. 2006 Oct;3(10):e420.
    4. Yuan, B.; Xu, Y.; Woo, J.H.; Wang, Y.; Bae, Y.K.; Yoon, D.S.; Wersto, R.P.; Tully, E.; Wilsbach, K.; Gabrielson, E. Increased expression of mitotic checkpoint genes in breast cancer cells with chromosomal instability. Clin Cancer Res. 2006 Jan 15;12(2):405-410.
    5. Lee, J.S.; Orita, H.; Gabrielson, K.; Alvey, S.; Hagemann, R.L.; Kuhajda, F.P.; Gabrielson, E.; Pomper, M.G. FDG-PET for pharmacodynamic assessment of the fatty acid synthase inhibitor C75 in an experimental model of lung cancer. Pharm Res. 2007 Jun;24(6):1202-1207.
    6. Orita, H.; Coulter, J.; Lemmon, C.; Tully, E.; Vadlamudi, A.; Medghalchi, S.M.; Kuhajda, F.P.; Gabrielson, E. Selective inhibition of fatty acid synthase for lung cancer treatment. Clin Cancer Res. 2007 Dec 1;13(23):7139-7145.
    7. Woo, J.H.; Li, D.; Wilsbach, K.; Orita, H.; Coulter, J.; Tully, E.; Kwon, T.K.; Xu, S.; Gabrielson, E. Coix Seed Extract, a Commonly Used Treatment for Cancer in China, Inhibits NFkappaB and Protein Kinase C Signaling. Cancer Biol Ther. 2007 Oct 13;6(12).
    8. Brock, M.V.; Hooker, C.M.; Ota-Machida, E.; Han, Y.; Guo, M.; Ames, S.; Glockner, S.; Piantadosi, S.; Gabrielson, E.; Pridham, G.; Pelosky, K.; Belinsky, S.A.; Yang, S.C.; Baylin, S.B.; Herman, J.G. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med. 2008 Mar 13;358(11):1118-1128.
    9. Gabrielson, K.L.; Mok, G.S.; Nimmagadda, S.; Bedja, D.; Pin, S.; Tsao, A.; Wang, Y.; Sooryakumar, D.; Yu, S.J.; Pomper, M.G.; Tsui, B.M. Detection of dose response in chronic doxorubicin-mediated cell death with cardiac technetium 99m annexin V single-photon emission computed tomography. Molecular imaging : official journal of the Society for Molecular Imaging. 2008 May-Jun;7(3):132-138.
    10. Garrett-Mayer, E.; Parmigiani, G.; Zhong, X.; Cope, L.; Gabrielson, E. Cross-study validation and combined analysis of gene expression microarray data. Biostatistics. 2008 Apr;9(2):333-354.
    11. Moens, A.L.; Takimoto, E.; Tocchetti, C.G.; Chakir, K.; Bedja, D.; Cormaci, G.; Ketner, E.A.; Majmudar, M.; Gabrielson, K.; Halushka, M.K.; Mitchell, J.B.; Biswal, S.; Channon, K.M.; Wolin, M.S.; Alp, N.J.; Paolocci, N.; Champion, H.C.; Kass, D.A. Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy. Circulation. 2008 May 20;117(20):2626-2636.
    12. Orita, H.; Coulter, J.; Tully, E.; Kuhajda, F.P.; Gabrielson, E. Inhibiting fatty acid synthase for chemoprevention of chemically induced lung tumors. Clin Cancer Res. 2008 Apr 15;14:2458-2464.
    13. Singh, A.; Boldin-Adamsky, S.; Thimmulappa, R.K.; Rath, S.K.; Ashush, H.; Coulter, J.; Blackford, A.; Goodman, S.N.; Bunz, F.; Watson, W.H.; Gabrielson, E.; Feinstein, E.; Biswal, S. RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res. 2008 Oct 1;68(19):7975-7984.
    14. Song, H.; Shahverdi, K.; Huso, D.L.; Wang, Y.; Fox, J.J.; Hobbs, R.F.; Gimi, B.; Gabrielson, K.L.; Pomper, M.G.; Tsui, B.M.; Bhujwalla, Z.; Reilly, R.T.; Sgouros, G. An immunotolerant HER-2/neu transgenic mouse model of metastatic breast cancer. Clin Cancer Res. 2008 Oct 1;14(19):6116-6124.
    15. Sussan, T.E.; Jun, J.; Thimmulappa, R.; Bedja, D.; Antero, M.; Gabrielson, K.L.; Polotsky, V.Y.; Biswal, S. Disruption of Nrf2, a key inducer of antioxidant defenses, attenuates ApoE-mediated atherosclerosis in mice. PLoS ONE. 2008;3(11):e3791.
    16. Suzuki, H.; Toyota, M.; Carraway, H.; Gabrielson, E.; Ohmura, T.; Fujikane, T.; Nishikawa, N.; Sogabe, Y.; Nojima, M.; Sonoda, T.; Mori, M.; Hirata, K.; Imai, K.; Shinomura, Y.; Baylin, S.B.; Tokino, T. Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer. Br J Cancer. 2008 Mar 25;98(6):1147-1156.
    17. Takahashi, K.; Miyashita, M.; Makino, H.; Akagi, I.; Orita, H.; Hagiwara, N.; Nomura, T.; Gabrielson, E.W.; Tajiri, T. Expression of Akt and Mdm2 in human esophageal squamous cell carcinoma. Exp Mol Pathol. 2008 Dec 14.
    18. Balmanoukian, A.; Zhang, Z.; Jeter, S.; Slater, S.; Armstrong, D.K.; Emens, L.A.; Fetting, J.H.; Wolff, A.C.; Davidson, N.E.; Jacobs, L.; Lange, J.; Tsangaris, T.N.; Zellars, R.; Gabrielson, E.; Stearns, V. African American women who receive primary anthracycline- and taxane-based chemotherapy for triple-negative breast cancer suffer worse outcomes compared with white women. J Clin Oncol. 2009 Aug 1;27(22):e35-37; author reply e38-39.
    19. Sussan, T.E.; Rangasamy, T.; Blake, D.J.; Malhotra, D.; El-Haddad, H.; Bedja, D.; Yates, M.S.; Kombairaju, P.; Yamamoto, M.; Liby, K.T.; Sporn, M.B.; Gabrielson, K.L.; Champion, H.C.; Tuder, R.M.; Kensler, T.W.; Biswal, S. Targeting Nrf2 with the triterpenoid CDDO-imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice. Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):250-255.
    20. Takahashi, K.; Miyashita, M.; Makino, H.; Akagi, I.; Orita, H.; Hagiwara, N.; Nomura, T.; Gabrielson, E.W.; Tajiri, T. Expression of Akt and Mdm2 in human esophageal squamous cell carcinoma. Exp Mol Pathol. 2009 Aug;87(1):42-47.
    21. Blake, D.J.; Singh, A.; Kombairaju, P.; Malhotra, D.; Mariani, T.J.; Tuder, R.M.; Gabrielson, E.; Biswal, S. Deletion of Keap1 in the lung attenuates acute cigarette smoke-induced oxidative stress and inflammation. Am J Respir Cell Mol Biol. 2010 May;42(5):524-536.
    22. Orita, H.; Coulter, J.; Tully, E.; Abe, M.; Montgomery, E.; Alvarez, H.; Sato, K.; Hino, O.; Kajiyama, Y.; Tsurumaru, M.; Gabrielson, E. High levels of fatty acid synthase expression in esophageal cancers represent a potential target for therapy. Cancer Biol Ther. 2010 Sep;10(6):549-554.
    23. Peterson, R.A.; Gabrielson, K.L.; Johnson, G.A.; Pomper, M.G.; Coatney, R.W.; Winkelmann, C.T. Continuing Education Course #1: Non-Invasive Imaging as a Problem-Solving Tool and Translational Biomarker Strategy in Toxicologic Pathology. Toxicol Pathol. 2010 Dec 8.
    24. Stoll, L.M.; Johnson, M.W.; Gabrielson, E.; Askin, F.; Clark, D.P.; Li, Q.K. The utility of napsin-A in the identification of primary and metastatic lung adenocarcinoma among cytologically poorly differentiated carcinomas. Cancer Cytopathol. 2010 Dec 25;118(6):441-449.
    25. Bhang, H.E.; Gabrielson, K.L.; Laterra, J.; Fisher, P.B.; Pomper, M.G. Tumor-specific imaging through progression elevated gene-3 promoter-driven gene expression. Nat Med. 2011 Jan;17(1):123-129.

    Lab

    Dr. Gabrielson’s lab has researched chromosomal changes in cancers, leading to the recognition that most cancers have an intrinsic instability of their genome. The lab has characterized chromosomal instability in breast cancer, recognizing that there are at least two different classes of breast cancers, based on different levels of instability. Those cancers with high levels of instability have mitotic spindle damage checkpoint defects, and the lab is investigating the possible role of known checkpoint genes in causing these defects.

    The Gabrielson lab works on proteins that mediate cell-cell interactions or cellular metabolism is an extension of their work on gene expression and cancer classification. They have found that a significant number of proteins that mediate cell-cell communications (e.g., e-cadherin, connexins) have decreased expression in breast cancer and lung cancer. We are now undertaking investigations to determine the mechanism of the decreased expression and the functional significance of this decreased expression in the cancer cells. Altered expression of proteins that mediate cellular metabolism is interesting, not only because of implications regarding the pathogenesis of cancer, but also because of potential therapeutic opportunities.

    The lab’s gene expression and protein activation studies are finding that the alterations in cellular metabolism affect pathways for glucose metabolism as well as fatty acid metabolism. Recently, they found that a small molecule compound that inhibits the enzymatic function of fatty acid synthase is an effective treatment for mesothelioma xenografts, and they are further investigating this compound for treatment of lung cancer.

  • Academic Affiliations & Courses +

    Graduate Program Affiliation

    Pathology

    Cellular and Molecular Medicine

  • Activities & Honors +
  • Videos & Media +
  • Events +
  • Contact & Locations +

    Locations

    The Johns Hopkins Hospital
    600 N. Wolfe Street
    Hospital Main Entrance - Sheikh Zayed Tower
    Baltimore, MD 21287
    Phone: 410-502-5250
    Appointment Phone: 410-502-5250
    Location Map
    Johns Hopkins Bayview Medical Center
    4940 Eastern Avenue
    Baltimore, MD 21224
    Phone: 410-502-5250
    Appointment Phone: 410-502-5250
    Location Map

    Department/Division

    • Pathology

Is This You? Edit Profile

 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.